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Splenic red pulp macrophages (RPM) contribute to erythrocyte homeostasis and are 
required for iron recycling. Heme induces the expression of SPIC transcription factor 
in monocyte-derived macrophages, and promotes their differentiation into RPM 
precursors, pre-RPM. However, the requirements for differentiation into mature RPM 
remain unknown. Here, we have demonstrated that interleukin (IL)-33 associated 
with erythrocytes and co-cooperated with heme to promote the generation of mature 
RPM through activation of the MyD88 adaptor protein and ERK1/2 kinases 
downstream of the interleukin 33 receptor, IL1RL1. IL-33 and IL1RL1 deficient mice 
showed defective iron-recycling and increased splenic iron deposition. Gene 
expression and chromatin accessibility studies revealed a role for GATA transcription 
factors downstream of IL-33 signaling during the development of pre-RPM that 
retained full potential to differentiate into RPM. Thus, IL-33 instructs the development 
of RPM as a response to physiological erythrocyte damage with important 
implications to iron recycling and iron homeostasis. 
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Introduction 
The development of tissue-resident macrophages from yolk sac-derived pre-
macrophages (Mass et al., 2016) or bone marrow-derived monocytes (Scott et al., 
2016) requires local specification by instructive signals coming from the tissue 
microenvironment (Amit et al., 2016; Gautier et al., 2014; Okabe and Medzhitov, 
2014). This is the case for some locally generated metabolites like retinoic acid, 
which is required for the polarisation of peritoneal macrophages, and heme which 
plays an essential role in the commitment of monocytes to a pre-red pulp 
macrophage (RPM) phenotype, dependent on the transcription factor SPIC (Amit et 
al., 2016; Haldar et al., 2014; Okabe and Medzhitov, 2014). An important 
physiological function of RPM is the regulation of iron metabolism through 
erythrocyte clearance and iron recycling. RPM phagocytose other blood-borne 
particulates and express several innate immune receptors, and may therefore be 
involved in the regulation of immune-inflammatory responses. RPM are also involved 
in type I interferon production in response to parasites (P. Chabaudi), and are able to 
cross-prime early effector T cell responses against viruses, and may therefore play a 
role in the defense against infections (Borges da Silva et al., 2015; Enders et al., 
2020; Kurotaki et al., 2015). 
Cytokines are important modulators of macrophage phenotype and function during 
inflammation and tissue repair (Bosurgi et al., 2017; Howangyin et al., 2016; Ip et al., 
2017; Jenkins et al., 2011; Minutti et al., 2017). However, the requirement for a local 
sources of cytokines during the homeostatic development and local specification of 
tissue-resident macrophages is not established (Amit et al., 2016). For example, local 
production of interleukin-34 (IL-34) in brain and skin is required for the development 
of microglia and Langerhans cells (Wang et al., 2012). However, in this case IL-34 
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mostly acts as a local colony stimulating factor-1 receptor (CSF1R) ligand required 
for monocyte and/or macrophage survival and proliferation rather than being involved 
in the functional specialisation to the microglial or Langerhans cell phenotype. 
Transforming growth factor-β1 (TGF-β1) is also essential for the acquisition of 
microglia and Langerhans cell signatures (Butovsky et al., 2014). However, the 
source of TGF-β1 has not been defined, and it is still unknown whether TGF-β1 
signaling is required for microglia development in a cell-autonomous manner. 
Furthermore, granulocyte macrophage-colony stimulating factor (GM-CSF) plays a 
specific role in the development of alveolar macrophages (Guilliams et al., 2013; 
Hashimoto et al., 2013), though it is unclear whether a specific local source of GM-
CSF is required for this effect. In addition, IL-10 is essential for the control of 
macrophage inflammatory responses through metabolic reprogramming of 
macrophages, inhibition of mammalian target of rapamycin (mTOR) signaling, and 
promotion of mitophagy (Ip et al., 2017). IL-4 is also involved in the proliferation of 
tissue-resident macrophages in response to type 2 inflammation (Jenkins et al., 
2011), and is required together with IL-13 for the induction of a tissue repair 
macrophage phenotype after type 2-mediated macrophage activation (Bosurgi et al., 
2017; Minutti et al., 2017), and aseptic ischemic injury (Howangyin et al., 2016). 
However, those cytokines are not required for the establishment of tissue-resident 
macrophages under homeostatic conditions. 
IL-33 is a member of the IL-1 cytokine family which plays a crucial role in initiation 
and amplification of immune responses to combat injury and infection (Cayrol and 
Girard, 2018; Liew et al., 2016; Scott et al., 2018b). IL-33 is constitutively expressed 
in the nucleus of epithelial cells in barrier tissues and endothelial cells of blood 
vessels. On release from damaged cells IL-33 activates many different immune cell 
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types via its receptor, interleukin receptor-like 1 (IL1RL1 also known as ST2). 
However, direct roles for IL-33 activity in regulating cellular differentiation and 
functions of mononuclear cell functions have remained poorly understood. It has 
been reported that IL1RL1 is not expressed on macrophages at steady state but can 
be induced (Kearley et al., 2015) and IL-33 signaling has been implicated in 
regulating osteoclast and macrophage foam cell formation (Kiyomiya et al., 2015; 
McLaren et al., 2010; Velickovic et al., 2015; Zaiss et al., 2011). Recent studies have 
highlighted the role of stromal-derived IL-33 in the generation of a pro-tumorigenic 
M2-like macrophage phenotype (Andersson et al., 2018), and the role of astrocyte-
derived IL-33 in promoting microglial-dependent synapse engulfment and depletion, 
thereby affecting neural circuit function (Vainchtein et al., 2018). 
The identity of the instructive signals required for the differentiation of pre-RPM into a 
mature RPM phenotype remains unknown. Given the prominent roles of cytokines in 
the modulation of macrophage phenotype and function, we hypothesised their 
potential involvement in the generation of RPM. Here, we show that IL-33 signaling 




We used previously validated assays of hemin-mediated induction of monocyte 
differentiation into an iron-recycling macrophage phenotype (Haldar et al., 2014) to 
survey potential roles of type 1 and type 2 cytokines on this process in the presence 
and absence of heme. We found that only IL-33 produced a significant increase in 
gene expression of markers of RPM phenotype (Figure 1A, and Figure S1A). IL-33 
alone had a limited impact. However, co-stimulation of macrophages with IL-33 and 
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hemin led to a substantial increase of hemin-induced expression of Spic (Figure 1A). 
Other prototypic genes of iron-recycling macrophages, including Treml4, Vcam1, 
Hmox1, were significantly upregulated (Figure 1A), whereas the expression of Bach1, 
a transcriptional repressor of Spic (Haldar et al., 2014), was not altered (Figure 1A). 
Of note, IL-33 alone substantially induced the expression of Lcn2 (Figure 1A), which 
encodes a protein (Lipocalin-2) that regulates iron transport and limits microbial 
growth through sequestration of iron-containing siderophores (Xiao et al., 2017), 
further supporting a role for IL-33 in the induction of an iron-recycling red pulp 
macrophage (RPM) phenotype. We obtained similar results with IL-33 in human 
CD14+ monocyte-derived macrophages (Figure S1B). 
We then purified splenic monocytes, pre-RPM and RPM, and stimulated them in vitro 
with hemin in the presence or absence of IL-33. First, we confirmed using the 
Spicigfp/igfp reporter mice (Haldar et al., 2014) that splenic RPM (CD11blo/- F4/80hi) are 
Spic-EGFPhi whereas splenic pre-RPM (CD11bhi F4/80lo) are Spic-EGFPlo/int (Figure 
S1C), and splenic monocytes (CD11bhi F4/80-) express little SPIC (not shown). This 
was further confirmed by gene expression analysis on sorted populations of splenic 
monocytes, pre-RPM and RPM, which revealed intermediate expression of RPM-
associated genes in pre-RPM compared to monocytes and RPM (Figure S1D). This 
supports the previous demonstration of a developmental continuum between these 3 
cell subsets (Haldar et al., 2014). Furthermore, we found that IL-33 had a substantial 
impact on hemin-induced Spic expression only in purified pre-RPM (Figure S1E), 
with no detectable effect in splenic monocytes (Figure S1E) and splenic RPM (data 
not shown). These results suggested a potential requirement of IL-33 to induce the 
differentiation of pre-RPM into RPM. To test this hypothesis in vivo, we treated mice 
with hemin, IL-33, or both, and assessed the induction of pre-RPM and RPM. In 
	 8	
agreement with previous work (Haldar et al., 2014), we found that hemin 
administration for 3 days increased the population of CD11bhi Spic-EGFPlo F4/80lo 
(Figure 1B-1E and Figures S1F-S1H) pre-RPM, but was unable to induce the 
generation of CD11b lo/- F4/80hi Spic-EGFPhi RPM (Figure 1B-1E and Figures S1F-
S1H). In contrast, co-administration of IL-33 with hemin led to a substantial increase 
of the CD11b lo/- Spic-EGFPhi F4/80hi RPM (Figure 1B-1E and Figures S1F-S1H). 
The IL-33 receptor, IL1RL1, mediates IL-33 signaling. IL1RL1 deficiency did not alter 
hemin-induced gene expression in monocyte-derived macrophages in vitro, but 
completely abrogated IL-33-dependent upregulation of Spic and other RPM-
associated genes (Figure S2A). To address the requirement of IL1RL1 in RPM 
development in vivo, we analysed IL1RL1-deficient mice (Figure S2B for IL1RL1 
expression on RPM) at different time points. We found that both the percentage of 
RPM (Figure 2A) and SPIC expression (Figures S2C and S2D) increased with age 
from neonatal day 1 and day 2 to 4 weeks or 6 weeks of age in wild type (WT) mice. 
IL1RL1 deficiency had no impact on RPM number in neonates but resulted in a 
significant ∼50% and ∼80% reduction in RPM number compared to WT mice at 6 and 
42 weeks of age, respectively (Figure 2A and Figure S2E). This was supported by a 
substantial reduction of F4/80+ staining in spleen sections of IL1RL1 deficient mice 
compared to WT mice at 42 weeks (Figure 2B). There was no impact of IL1RL1 
deficiency on other splenic cell types (Figure S2F) or liver Kupffer macrophages 
(data not shown). Consistent with these data, we found that treatment of adult 
Spicigfp/igfp reporter mice with murine soluble IL1RL1-Fc fusion protein for 6 weeks, to 
block IL-33 signaling, significantly reduced the percentage of Spic-EGFPhi CD11blo/- 
RPM (without affecting pre-RPM number) in comparison with mice that received 
murine IgG1 (Figures 2C). We then generated mixed bone marrow chimeras (50% 
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CD45.2 WT or 50% IL1RL1 deficient  CD45.2 bone marrow + 50% CD45.1 WT bone 
marrow into irradiated CD45.2 WT mice) to address the cell-autonomous requirement 
of IL1RL1 expression in bone marrow-derived monocytes for their differentiation into 
RPM (Figure S3A). We found that splenic monocytes and pre-RPM were generated 
at similar frequencies from the CD45.1 and CD45.2 bone marrow, under the basal 
state or after combined hemin and IL-33 stimulation, whatever the status of IL1RL1 
expression (Figure S3B). By contrast, most RPM in the 50% CD45.2 IL1RL1 deficient 
+ 50% CD45.1 WT group originated from the CD45.1 bone marrow (Figure S3C), 
indicating a profound alteration of RPM generation in the absence of IL1RL1 
expression in monocytes and pre-RPM. We also lethally irradiated CD45.1 WT mice 
and reconstituted them with CD45.2 bone marrow originating from either WT or 
IL1RL1 deficient mice. Similarly, we found a marked defect in RPM generation from 
the CD45.2 IL1RL1 deficient bone marrow compared to CD45.2 WT bone marrow 
(Figures S3D-S3F). 
We then addressed the functional impact of these findings. We found that the uptake 
of PKH26-labeled red blood cells (RBCs) in vivo was reduced in RPM, but not pre-
RPM or other cell types, in the absence of IL1RL1 (Figures S4A and S4B), 
suggesting defective iron-recycling capacity. Next, we measured iron stores in young 
(6 weeks old) and old (42 weeks old) WT and IL1RL1 deficient mice. While we found 
no difference in serum iron concentrations between mouse groups (Figure 3A), we 
detected a significant increase of spleen weight (Figure 3B) and a 3-fold increase of 
splenic tissue iron concentration in 42 week old IL1RL1 deficient mice compared to 
WT controls (Figure 3C). Substantial iron accumulation was confirmed histologically 
on splenic tissue sections (Figure 3D). In case of defective iron recycling in spleen, 
the liver can increase its iron-recycling capacity through increased recruitment of 
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circulating monocytes and their differentiation into iron-recycling macrophages 
(Theurl et al., 2016). We found iron concentrations in liver were also substantially 
increased in old IL1RL1 deficient compared to WT controls (Figure 3E), suggesting 
that the iron-recycling capacity of liver macrophages was overwhelmed. Old IL1RL1 
deficient mice (42 weeks) did not show evidence of anemia (Figure S4C). However, 
serum ferritin concentration was substantially higher in old IL1RL1 deficient mice 
compared to WT controls (Figure S4C). Taken together, our data identify a major role 
for the IL1RL1 signaling pathway in the differentiation of monocytes to iron-recycling 
RPM. 
We sought to examine which intracellular signaling pathways are involved in the 
process downstream of IL1RL1 activation. Myd88-/- mice displayed reduced numbers 
of RPM (but not monocytes or pre-RPM, not shown) at steady state, and did not 
increase their RPM after in vivo administration of IL-33 and hemin (Figure 4A). 
Several signaling pathways are activated downstream of MyD88 following IL1RL1 
engagement by IL-33 (Liew et al., 2016; Pinto et al., 2015). Using a human 
phosphokinase assay, we found that the combination of hemin and IL-33 led to 
increased ERK1/2 phosphorylation in monocyte-derived macrophages in vitro, 
compared to IL-33 alone (Figure 4B). MSK1/2 phosphorylation was also marginally 
increased in presence of IL-33 and hemin, however, there was no combined effect on 
any other signaling pathways surveyed (data not shown). We confirmed the effect of 
IL-33 and hemin on ERK1/2 phosphorylation in mouse bone marrow monocyte-
derived macrophages (Figure 4C). Next, we investigated the impact of in vivo 
inhibition of ERK1/2 for 6 weeks on RPM number. The MEK inhibitor U0126 
prevented ERK1/2 phosphorylation in spleen lysates (Figure 4D) and reduced RPM 
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(CD11b lo/- F4/80hi Spic-EGFPhi) number compared to vehicle-treated mice (Figure 
4E), without altering pre-RPM (CD11bhi Spic-EGFPlo F4/80lo) (Figure 4E).  
We next addressed the role of endogenous IL-33 in the modulation of RPM. Similar 
to IL1RL1 deficient mice, young and old IL-33 deficient mice displayed a substantial 
reduction of RPM compared to WT controls (Figures 5A, S2E, and S5A), and we 
were able to partially restore RPM counts in IL-33 deficient mice after treatment for 4 
days with IL-33 alone (Figure S5B), an effect that was further enhanced by the 
addition of hemin (Figure S5B). Like IL1RL1 deficient mice, old IL-33 deficient mice 
showed a significant increase of spleen weight, splenic tissue iron concentration, and 
liver iron accumulation compared to control mice (Figure 5B), strongly suggesting 
reduced iron-recycling capacity in the absence of IL-33. IL-33 deficient rats also 
showed a substantial reduction in CD11bloEMR1hi splenic macrophages (EMR1 is 
the homologue of F4/80) compared to control animals (Figure S5C), further 
supporting a role for IL-33 signaling in the development and/or maintenance of RPM. 
Next, we investigated the potential source of endogenous IL-33 that could modulate 
RPM. As IL-33 and hemin co-operated to promote the iron-recycling macrophage 
phenotype, we hypothesized that IL-33 might be co-expressed with hemin in 
erythrocytes. We therefore analysed IL-33 expression in RBCs and their progenitors. 
We detected a ~31 kDa full length form of IL-33 protein (Cayrol et al., 2018; Scott et 
al., 2018a) in WT, but not IL-33 deficient murine erythrocyte lysates (Figure 5C). 
Human IL-33 was weakly detectable in full length form but was predominantly 
detected as a ~29 kDa form in human erythrocyte lysates (Figure 5C, and data not 
shown). This ~29 kDa form was also seen in the recombinant full length control 
(Figure 5C and Figure S6A), and was detected in highly enriched CD235a+ human 
erythrocytes using 2 additional anti-IL-33 antibodies (Figure S6A). IL-33 protein 
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expression in human erythrocyte lysates was confirmed by ELISA (Figure 5D and 
Figure S6B). We explored mechanisms for the association of IL-33 by erythrocytes. 
One possibility is that erythroid precursors express IL-33. Another possibility is that 
erythrocytes bind IL-33, either via IL1RL1 dependent or independent pathways. 
Using Il33-Citrine reporter mice, we found that only ∼5% of erythrocyte progenitors 
expressed IL-33 (Figure S6C), broadly consistent with low amounts of IL-33 in 
mature erythrocytes. Among bone marrow cells, IL1RL1 was preferentially expressed 
in erythroid progenitors (stage B erythroblasts (Koulnis et al., 2011)), but not mature 
erythrocytes (Figure S6D and data not shown), and was capable of binding and 
internalising recombinant IL-33 (Figure S6E). Consistent with this observation, we 
found that IL-33 was significantly lower in erythrocyte lysates of IL1RL1 deficient 
mice compared to WT mice (Figure 5D). We then addressed the in vivo relevance of 
erythrocyte-associated IL-33 to the development of RPM. Notably, reconstitution of 
IL-33 deficient mice with WT, but not IL-33-deficient erythrocytes predominantly 
restored RPM without affecting pre-RPM numbers (Figure 5E), whereas 
reconstitution of IL-33 deficient mice with erythrocytes from IL1RL1 deficient mice 
partially restored RPM numbers (Figure S6F). Thus, erythrocytes can provide both 
heme and IL-33 to induce the development of monocyte-derived RPM. However, it is 
plausible that IL-33 expressed by other cell types in the spleen may also contribute 
IL-33 to enable the development of RPM.  
To provide further mechanistic insight into how IL1RL1 dependent IL-33 signaling 
promotes the development of monocyte-derived RPM, we compared the 
transcriptomes of splenic monocytes, pre-RPM and RPM from WT and IL1RL1 
deficient mice (Figure 6 and Tables S1 to S3). The global gene expression profile of 
each cell-type was very similar for WT and IL1RL1 deficient mice (Figure 6A and 6B, 
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respectively). However, we identified a small number of differentially expressed 
genes between WT and IL1RL1 deficient splenocytes, with most differences in the 
pre-RPM cell population (Table S2), consistent with our prior observations that IL-33 
promotes the development of RPM from pre-RPM in vivo.   
We performed pathway analysis to identify potential transcriptional regulators of the 
genes that were differentially expressed between monocytes and pre-RPM and 
between pre-RPM and RPM. Many of the same upstream regulators were identified 
in WT and in IL1RL1 deficient mice (Figure 6C). However, we noted that the 
transcription factors GATA2 and ETS1 (which is potentially regulated by GATA2 
(Linnemann et al., 2011)), were implicated in the differentiation of monocytes to pre-
RPM and down-regulated in IL1RL1 deficient pre-RPM (Figure 6D and Table S2).  
To further investigate the changes in gene expression that govern the differentiation 
of monocytes to RPM, we assessed chromatin accessibility by ATACseq and then 
performed motif enrichment analysis to identify potentially important transcription 
factor binding sites in accessible regions, in splenic monocytes, pre-RPM and RPM 
from WT and IL1RL1 deficient mice (Figure S7A and Table S4). There was a high 
degree of overlap in the accessible chromatin regions of each cell-type between WT 
and IL1RL1 deficient mice (Figure S7A). However, GATA motifs were specifically 
enriched in monocytes, in genes that were down-regulated from monocytes to pre-
RPM, and in pre-RPM, in genes that were down-regulated from pre-RPM to RPM, 
from WT but not IL1RL1 deficient mice (Figure 7A and Table S4). Indeed, accessible 
regions of chromatin that were unique to WT (i.e. inaccessible in IL1RL1 deficient 
mice) were enriched for GATA motifs within 100kb of genes that were dynamically 
regulated in monocytes to pre-RPM and in pre-RPM to RPM (Figure 7A). Thus, 
analysis of chromatin accessibility by ATAC-seq provided independent evidence for a 
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role of GATA transcription factor signaling downstream of IL1RL1 in the development 
of monocyte-derived RPM. 
Expression of Gata2 and Gata3 was strongly down-regulated, whilst Gata1 
expression was induced, in the differentiation of monocytes to RPM, in both WT and 
IL1RL1 deficient mice (Figure 7B). This pattern of gene expression is consistent with 
a ‘GATA switch’, in which GATA1 replaces GATA2 at regulatory elements to affect 
changes in gene expression, as is well documented in other pathways of 
hematopoiesis (Bresnick et al., 2010). GATA1 was identified, alongside GATA2, as 
another potentially upstream regulator of the genes differentially expressed from 
monocytes to pre-RPM, indicating a GATA switch may indeed be involved in 
regulating this transition. However, there was a marked difference in the dynamics of 
Gata2 expression in WT and IL1RL1 deficient mice (Figure 7B). In WT mice, Gata2 
expression was down-regulated upon differentiation of pre-RPM to RPM, however, in 
IL1RL1 deficient mice, expression of Gata2 was down-regulated earlier, upon 
differentiation of monocytes to pre-RPM (Figure 7B). It is likely that such a decrease 
in Gata2 expression at this earlier stage would accentuate the GATA switch 
dependent changes in gene expression in the transition of monocytes to pre-RPM, in 
IL1RL1 deficient mice compared to WT mice. Indeed, although the transcriptomes of 
WT and IL1RL1 deficient pre-RPM were very similar, pathway analysis identified 
GATA2 and ETS1 as potential upstream regulators of most of the genes that were 
differentially expressed in WT versus IL1RL1 deficient pre-RPM (Figure S7B). 
However, most compellingly, almost all of the genes that were differentially 
expressed between WT and IL1RL1 deficient pre-RPM could be accounted for by 
accentuated changes in gene expression in the transition of monocytes to pre-RPM 
in IL1RL1 deficient mice compared to WT mice (Figure 7C).Combined, this data 
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supports a role for IL1R1 dependent signaling in regulating the expression of GATA2, 
which is a key orchestrator of the transcriptional events in the development of 
monocyte-derived pre-RPM that are capable of maturing to RPM.   
 
Discussion 
Local environmental cues are important in the specification of tissue-resident 
macrophages. This is the case for erythrocyte-derived heme that induces the 
expression of SPIC in monocytes, and contributes to the RPM differentiation 
programme by establishing a precursor pre-RPM phenotype (Haldar et al., 2014). 
Here, we have shown that IL-33 signaling via its receptor, IL1RL1, is required for the 
optimal generation of mature monocyte-derived RPM. Mechanisms for how IL-33 
regulates the functions of mononuclear cells have remained obscure despite roles in 
regulating mononuclear cell phenotypes (Andersson et al., 2018; Kiyomiya et al., 
2015; McLaren et al., 2010; Vainchtein et al., 2018; Velickovic et al., 2015; Zaiss et 
al., 2011). Here, we implicated a role for IL-33 signaling in maintaining GATA2 
activity that is important in regulating the changes in gene expression which, at least 
in part, instructed the transition of monocytes to pre-RPM. By regulating GATA2 
expression, IL-33 signaling influenced this transition to produce pre-RPM that were 
competent to go on to fully differentiate to RPM. In contrast, in the absence of IL-33 
signaling, aberrant GATA2 expression led to terminal differentiation at a pre-RPM-
like stage. Further resolution of the signaling pathways involved in the cooperation 
between heme and IL-33 for the development of mature RPM will require additional 
investigations, however, our studies highlight a role for IL-33 combined with hemin in 
driving ERK1/2 activation, which culminates in fine-tuning of Gata2 expression. The 
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implication of ERK1/2 in the process was inferred from studies using a MEK inhibitor, 
and will therefore require validation using genetic silencing.  
GATA2 is an established regulator of myelopoiesis, with well-documented context 
and dose-dependent effects on stem and progenitor cell proliferation, quiescence, 
self-renewal and differentiation (Kitajima et al., 2006; Ling et al., 2004; Nandakumar 
et al., 2015). Gata2 expression is highest in stem and progenitor cells and down-
regulated during commitment in the monocyte lineage (Akashi et al., 2000). Further 
studies are required to ascertain the downstream effects of GATA2 that confer 
competency to pre-RPM to continue to differentiate to RPM, although our data 
implicate a potentially important role for a GATA switch, similar to those previously 
shown to regulate the expression of a number of GATA2 target genes, including 
Gata2 itself and some lineage specific transcription factors, such as the monocyte 
and macrophage lineage transcription factor PU.1 (also known as Sfpi1) (Chou et al., 
2009). Interactions between GATA1 and heme have previously been implicated in 
the control of erythropoiesis, notably in regulating the expression of genes involved in 
heme biosynthesis (Tanimura et al., 2016), and many of these genes were 
differentially expressed in the development of monocytes to RPM (data not shown). 
Previous studies have also highlighted a role for a ‘definitive-hematopoiesis-specific’ 
enhancer region, containing GATA, Ets, and AP-1 binding sites, 9.5kb downstream of 
the Gata2 transcriptional start site (Gao et al., 2013; Johnson et al., 2012). We found 
this region was accessible in WT but not IL1R1 deficient pre-RPM (data not shown). 
We speculate that IL-33 mediated activation of ERK1/2 may regulate the recruitment 
of transcription factors to Gata2 regulatory elements, such as the +9.5 enhancer, to 
regulate Gata2 expression in the development of monocytes to pre-RPM. 
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Here we sought to clarify sources of IL-33 required for RPM development. We have 
discovered that native erythrocytes accumulate IL-33 and that erythrocyte-associated 
IL-33 is sufficient for RPM development in vivo. Erythrocytes have been shown to 
play a role in the storage and release of cytokines although IL-33 was not 
investigated (Karsten et al., 2018). To date evidence for expression of IL-33 on 
hematopoietic cells is very limited, however, its noteworthy that platelets and in vitro 
cultured CD34+ erythroid progenitors were reported to express IL-33 (Takeda et al., 
2016; Wei et al., 2015). Here we have provided evidence for the existence of IL-33 in 
erythrocytes, using multiple techniques and supported by specificity controls, 
including samples from IL-33 deficient mice and highly purified erythrocyte 
preparations. In contrast to the detection of full length IL-33 in murine erythrocytes, 
we found IL-33 in human erythrocyte preparations was highly susceptible to 
proteolytic processing. Full length IL-33 is biologically active, however, it is possible 
that proteolytic processing might regulate IL-33 activity (Lefrancais et al., 2014; Scott 
et al., 2018a). We could not rule out this processing might have occurred during ex-
vivo handling and further work is required to understand the nature of this processing 
and its biological relevance. 
We explored mechanisms underlying the accumulation of IL-33 in erythrocytes. IL-33 
localises to the nucleus in nucleated cells, and it is unclear how IL-33 is stored in 
erythrocytes lacking a cell nucleus. We have found evidence for IL-33 gene 
transcription in bone-marrow-derived erythrocyte precursors consistent with studies 
in related hematopoietic cell precursors (Takeda et al., 2016; Wei et al., 2015). We 
also observed a partial role for IL1RL1 in acquiring and/or maintaining IL-33 in 
erythrocytes. However, overall our data is inconsistent with IL-33 detected in mature 
erythrocytes being maintained on the cell surface by IL1RL1. The ELISA used to 
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measure IL-33 in erythrocyte lysates does not detect IL-33 in complex with IL1RL1 
(I.C.S, E.S.C. personal communication) and we were unable to detect endogenous 
IL-33 on the surface of erythrocytes or erythrocyte precursors (data not shown). We 
demonstrated the expression of IL1RL1 with binding activity on erythrocyte 
precursors in the bone marrow. Although the function of IL1RL1 during erythrocyte 
development is poorly understood, there is evidence for a role for IL-33 signaling in 
enucleation of erythroid precursors (Lopez-Yrigoyen et al., 2019). Still, additional 
studies will be required to elucidate mechanisms by which erythrocytes maintain a 
store of IL-33 in the absence of a nucleus, and further investigate the role of IL1RL1 
in the bone marrow during the development of erythrocytes.  
In conclusion, we have shown that IL-33 is unique in its local requirement for the 
development and specification of a tissue-resident macrophage phenotype, and in its 
cooperation with an essential biochemical compound (heme) generated by the same 
source, to fulfil its homeostatic function. This pathway is essential for the normal 
regulation of iron recycling. Similarly to its role as an alarmin in initiating immune 
responses during tissue damage, IL-33 appears to act as an alarmin during 
physiological damage of senescent erythrocytes, thereby instructing the 
differentiation of a specific subset of tissue-resident macrophages involved in the 
clearance of senescent erythrocytes and the recycling of their iron content. Beyond 
its role in iron homeostasis and the response to erythrocyte damage, IL-33 might also 
be involved in other immunological properties of RPM, including the response to 
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Figure 1. IL-33 upregulates hemin-induced Spic expression and promotes the 
development of a red pulp macrophage (RPM) phenotype in vitro and in vivo. A, 
Gene expression in mouse bone marrow-derived macrophages stimulated in vitro for 
4 days with hemin (40 µM), IL-33 (10 ng/mL), or a combination of hemin + IL-33, 
compared to no treatment (NT). Data represent mean ± SEM and are representative 
of 5 independent experiments. **P<0.01, ****P<0.001. B-E, Representative examples 
(B) and quantification (among CD45+ CD11clow Ly6Glow NK1.1low SSC-Alow cells) of 
flow cytometry staining for splenic monocytes (CD11b+ F4/80-) (C), pre-RPM 
(CD11b+ F4/80lo) (D) and RPM (CD11blo/- F4/80hi) (E) in mice injected 
intraperitoneally once a day for 3 days with either phosphate buffered saline (PBS), 
IL-33 (1 µg), hemin (500 µg), or IL-33 + hemin. ****P<0.001. Data representative of at 
least 5 independent experiments. Please also see Figure S1. 
 
Figure 2. IL1RL1 signaling controls the development of splenic red pulp 
macrophages (RPM). A, Quantification (% among CD11clow Ly6Glow NK1.1low SSC-
Alow cells) of splenic pre-RPM (CD11bhi F4/80lo) and RPM (CD11blo/- F4/80hi) in 
neonates (Day 1), young (6 weeks), and old (42 weeks) WT and Il1rl1-/- mice. Each 
dot represents a separate mouse. ****P<0.001. B, Staining of RPM (F4/80 shown in 
green) in spleen sections of 42 week WT and Il1rl1-/- mice. C, Flow cytometry staining 
and quantification of splenic RPM (CD11blo/ Spic-EGFPhi) and pre-RPM (CD11b+ 
Spic-EGFPlo/int) (percentages among CD11clow Ly6Glow NK1.1low SSC-Alow cells) after 
6 weeks treatment of Spicigfp/igfp reporter mice with control murine IgG1 (mIgG1) or 
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soluble IL1RL1-murine Fc fusion protein (soluble IL1RL1). Each dot in the 
quantification panels represents a separate mouse. ****P<0.001. Please also see 
Figures S2 and S3. 
 
Figure 3. Impact of IL1RL1 signaling on the iron-recycling capacity of splenic 
red pulp macrophages (RPM). Quantification of serum iron (A), spleen weight (B), 
and spleen iron (C) in young (6 weeks) and old (42 weeks) WT and Il1rl1-/- mice. D, 
Representative examples (6 mice per group) of Perl’s blue staining (to detect iron) in 
spleen sections of young (6 weeks) and old (42 weeks) WT and Il1rl1-/- mice. Scale 
Unit: 300µm. E, Quantification of liver iron in young (6 weeks) and old (42 weeks) WT 
and Il1rl1-/- mice. Each dot represents a separate mouse. **P<0.01, ****P<0.001. 
Please also see Figure S4. 
 
Figure 4. MyD88 and ERK1/2 signaling downstream of IL-33 control the 
development of red pulp macrophages (RPM). A, Quantification of RPM (% 
among CD11clow Ly6Glow NK1.1low SSC-Alow cells) in spleens of wild type (WT) and 
Myd88-/- mice with or without treatment with hemin alone or IL-33 + hemin (one daily 
injection for 3 days, see Methods). B, Human macrophages (generated by culture of 
CD14+ monocytes from blood) treated for 5 min with phosphate buffered saline (NT), 
hemin (40 µM), IL-33 (10 ng/mL), or a combination of hemin + IL-33, and assessed 
using a phospho-kinase array. pERK1/2 is shown in red boxes. Quantification of the 
intensity of ERK1/2 phosphorylation signal (pixel density) was performed using 
ImageJ. Data represent mean ± SEM and are representative of 3 independent 
experiments. C, Mouse bone marrow-derived macrophages of WT and Il1rl1-/- mice 
treated in vitro for 5 min with PBS (NT), hemin, IL-33, or a combination of hemin + IL-
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33, and assessed for pERK1/2, ERK1/2 and phospho-p65 (NF-κB) using western 
blotting. Semi-quantification of signal intensity (mean ± S.E.M.) of ERK1/2 
phosphorylation (pERK/Total ERK) using ImageJ yielded WT IL-33: 0.74 ± 0.02 vs 
WT IL-33+Hemin: 1.24 ± 0.09, P<0.05. Semi-quantification of signal intensity (mean 
± S.E.M.) of p65 phosphorylation using ImageJ yielded WT IL-33: 11750 ± 3500 vs 
WT IL-33+Hemin: 12607 ± 4500, P=0.09. D, E, C57/Bl6 Spicigfp/igfp reporter mice 
were treated with ERK1/2 inhibitor U0126 or DMSO control for 6 weeks (see 
Methods). ERK1/2 phosphorylation in splenic extracts (D) and splenic CD11blow Spic-
EGFPhi RPM and CD11b+ Spic-EGFPint pre-RPM (percentages among CD11clow 
Ly6Glow NK1.1low SSC-Alow cells) (E) were quantified at the end of the experiment.  A 
control non-reporter untreated mouse (C57/Bl6) is included as control in D. Each lane 
in C and D represents a separate mouse. Each dot in E represents a separate 
mouse. ****P<0.001.  
 
Figure 5. Red blood cell-derived IL-33 controls the development of splenic red 
pulp macrophages (RPM). A, Quantification of RPM and pre-RPM (% among  
CD11clow Ly6Glow NK1.1low SSC-Alow cells) in spleens of young (6 weeks) and old (42 
weeks) wild type (WT) and Il33-/- mice. B, Quantification of serum iron, spleen weight, 
spleen iron, and liver iron in young (6 weeks) and old (42 weeks) WT and Il33-/- mice. 
C, Detection of IL-33 in human (top panel) and mouse (lower panel) red blood cell 
(RBC) lysates using western blotting. Recombinant full-length and processed human 
and mouse IL-33 are included as positive controls. RBC lysates from Il33-/- mice are 
included as negative controls. Each lane is from a separate mouse or individual, 
representative of at least 5 independent experiments. D, Quantification of IL-33 
protein in RBC lysates of WT, Il33-/- (negative control), and Il1rl1-/- mice. E, 
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Quantification (% among CD11clow Ly6Glow NK1.1low SSC-Alow cells) of splenic pre-
RPM (CD11bhi F4/80lo) and RPM (CD11blo/- F4/80hi) by flow cytometry in WT and Il3-/- 
mice. Some Il33-/- mice were reconstituted with either WT or Il33-/- RBCs (see 
Methods) prior to assessment of splenic pre-RPM and RPM. Each dot in A, B, D and 
E, represents a separate mouse. ****P<0.001. Please also see Figure S5 and S6. 
 
Figure 6. GATA2 is implicated in the development of splenic red pulp 
macrophages (RPM) and differentially expressed in WT and Ilrl1-/- pre-RPM. 
A and B, Heatmaps showing relative expression of genes differentially expressed 
between wild-type (WT) monocytes and WT pre-RPM (693 genes) or WT pre-RPM 
and WT RPM (3079 genes) respectively (log2 fold change >1, adjusted p-
value<0.01), in splenic monocytes (CD11bhi F4/80-), pre-RPM (CD11bhi F4/80lo ) and 
RPM (CD11blo/- F4/80hi), from WT and Il1rl1-/- mice, n=4 separate mice per group. C, 
Top upstream transcriptional regulators for transcriptomic changes from monocytes 
to pre-RPM or pre-RPM to RPM in WT and Il1rl1-/- mice, identified by Ingenuity 
pathway analysis. Note: the top regulators in each group were significant in both 
groups. D, Top differentially expressed genes in pre-RPM (CD11bhi F4/80lo) from WT 
and Il1rl1-/- mice, n=4 separate mice per group; complete list available online (Table 
S2). Please see also Figure S7. 
 
Figure 7. A GATA switch may underlie changes in gene expression in the 
development of splenic red pulp macrophages (RPM). 
A, Identification of GATA motifs in accessible chromatin of splenic monocytes 
(CD11bhi F4/80-), pre-RPM (CD11bhi F4/80lo ) and RPM (CD11blo/- F4/80hi), within 
100kb of the start sites of genes differentially expressed between wild-type (WT) 
monocytes and WT pre-RPM or WT pre-RPM and WT RPM (both log2 fold change>1, 
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adjusted p-value<0.05). Motif enrichment was performed on accessible chromatin 
from each splenocyte population from WT and Il1rl1-/- mice and also from accessible 
chromatin from each splenocyte population that was unique to WT or unique to Il1rl1-
/- mice, n=4 separate mice per group. B, Relative Gata gene expression (normalised 
counts, cpm) in splenic monocytes (CD11bhi F4/80-), pre-RPM (CD11bhi F4/80lo ) and 
RPM (CD11blo/- F4/80hi) of WT (green) and Il1rl1-/- mice (red), n=4 separate mice per 
group. Data are represented as mean ± SEM. **** adjusted p (WT v -/-) < 0.001. C, 
Heatmaps showing log2 fold changes of genes differentially expressed in WT and 
Il1rl1-/- pre-RPM (adjusted p-value <0.05) between splenic monocytes (CD11bhi 
F4/80-) and pre-RPM (CD11bhi F4/80lo) or pre-RPM (CD11bhi F4/80lo ) and RPM 







Lead author: Ziad Mallat, zm255@medschl.cam.ac.uk 
Methods, including statements of data availability and any associated additional 
references are available in the online version of the paper. 
Mice. All experiments were approved by the Home Office, UK. C57/Bl6 Spicigfp/igfp 
reporter mice were kindly provided by Kenneth M. Murphy (Washington University, 
St Louis), Balb/c background of Il1rl1-/- and Il33-/- were from Andrew McKenzie and 
C57/Bl6 background of Il1rl1-/- were from Padraic Fallon, C57/Bl6 Myd88-/- mice 
were from Bernhard Ryffel and C57/Bl6 CD45.1 mice were originally from Jackson 
Labs. For the hemin (500µg/200µl) and IL-33 (1µg/200µl) in vivo experiment, the 
mice were injected intra-peritoneally once a day for 3 days. Control mice received 
PBS (200µl) injections. For the ERK1/2 in vivo experiment, C57/Bl6 Spicigfp/igfp 
reporter mice were treated with the MEK inhibitor U0126 or DMSO control 3 times 
per week for 6 weeks. U0126 solution was prepared in DMSO as previously 
described (Marampon et al., 2009). Two hundred microliters 50 µmol/kg were 
injected intra-peritoneally into each mouse. For the soluble IL1RL1 (ST2) in vivo 
experiment, C57/Bl6 Spicigfp/igfp reporter mice were treated with soluble IL1RL1 or 
murine IgG1 control 200µg/mouse 3 times per week for 6 weeks. 
To reconstitute Il33-/- mice with erythrocyte-associated IL-33, Il33-/- mice received 
once a day for 3 days i.v. injections (200 µl) of 2x109 erythrocytes from either WT or 
Il33-/- mice. 
Hemin preparation. Hemin was purchased from Sigma-Aldrich (51280, Sigma), and 
a stock solution was prepared at 25mg/ml in 0.15M NaCl containing 10% NH4OH and 
stored at -20oC. Hemin was used at a final concentration of 40uM for cell culture 
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experiments and 500µg/200µl sterile 0.15M NaCl for i.p. injections in vivo, as 
previously described (Haldar et al., 2014). 
Bone marrow transplants. CD45.1 mice were maintained overnight with Baytril 
before irradiation with two doses of 5.5 Gy (separated by 4 h) followed by 
reconstitution with 107 bone marrow cells obtained from CD45.2 WT or Il1rl1-/- mice. 
Donor-derived cells in spleen or liver (CD45.2+) were analyzed 10 weeks after 
transfer using flow cytometry. In other experiments, CD45.2 mice were lethally 
irradiated and injected intravenously (i.v.) with 107 bone marrow cells containing 50% 
of CD45.2 WT or Il1rl1-/- mice and 50% of CD45.1 mice.  
Spleen, liver and serum iron analysis. Samples of the spleen (20-60 mg) and liver 
(40-90 mg) were digested (1 in 10) in 16% nitric acid, prepared by diluting a stock 
solution of high purity nitric acid (65% w/v p.a. plus; Sigma-Aldrich) with ultra-high 
purity water, in acid-cleaned 15 mL PTFE vials in an UltraWave Single Reaction 
Chamber Microwave Digestion System (Milestone Srl; Sorisole, Italy). The following 
digestion conditions were followed: 5 min ramp to 120°C, then 10 min ramp from 
120°C to 230°C and maintained at 230°C for 15 min. Blank samples, containing just 
the acid mixture, were similarly prepared to check for background Fe contributions.  
Digested samples were analysed for total Fe by inductively coupled plasma optical 
emission spectrometry (Jobin Yvon Horiba Ultima 2C; Instrument SA, Longjumeau, 
France), equipped with a concentric micro-nebulizer and cyclonic spray chamber. A 
sample introduction pump speed of 10 rates/min, nebulizer flow rate of 0.72 mL/min 
and a plasma gas flow rate of 10 L/min was used with low-flow sample tubing. The 
259.940 nm analytical line for Fe was used. All samples, including blank samples, 
were analyzed in a single batch with acid-based Fe standards (0-40 mg/L). Each 
sample was analysed in triplicate and the average value was used. For serum 
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measurements, 20 µl of serum was incubated with 20 µl of acid reagent for 5 min. 
Supernatant was mixed with 40 µl chromagen reagent, and absorbance at 535 nm 
was measured as described above. 
Histochemical analysis. For Perl’s Prussian blue stain, tissues were fixed with 4% 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.0), embedded in paraffin, and 
stained with Perl’s Prussian blue and pararosaniline (Sigma). 
Differentiation of bone marrow-derived macrophages. Fresh bone marrow cells 
were used to generate BMDM. Cells were resuspended in 10 ml bone marrow 
differentiation media (RPMI1640 supplemented with 10% fetal bovine serum (Gibco, 
cat. 12657-029), 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine and 
20ng/mL of M-CSF(BioLegend)). Cells were seeded in Petri dishes (Corning Brand) 
and incubated at 37°C in a 5% CO2 atmosphere. Four days after seeding, an extra 
10 ml of fresh differentiation media were added per plate and incubated for an 
additional 3 days.  
Flow cytometry. Single-cell suspensions of bone marrow, spleen and liver were 
incubated with Fc block solution (eBioscience, clone 93), dilution of 1:200 in flow 
buffer (PBS, 1 % BSA, 2 mM EDTA, 0.01 % NaN3) for 10 minutes at 4°C. Cells were 
then stained with fluorophore-conjugated antibodies, dilution of 1:200 in flow buffer 
for 30 minutes at 4°C, prior to extensive wash and analysed using an LSRII 
Fortessa (BD) flow cytometer. The following antibodies were used in the 
experiments, Zombie Aqua Fixable Viability Kit, Alexa Flour 700 anti-mouse CD11b 
(BD Bioscience MI170), PE/Cy7 anti-mouse CD11c (BioLegend N418), Brilliant 
Violet 421 anti-mouse F4/80 (BioLegend BM8), APC-eFluor 780 anti-mouse Ly6C 
(eBioscience HK1.4), PerCP/Cy5.5 anti-mouse Ly-6G (BioLegend 1A8), Brilliant 
Violet 650 anti-mouse NK-1.1 (BioLegend PK136), Brilliant Violet 605 anti-mouse 
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CD335 (BioLegend 29A1.4), FITC anti-mouse CD169 (BioLegend 3D6.112), APC 
anti-mouse CD209b (eBioscience eBio22D1), FITC anti-mouse T1/IL1RL1 (ST2) 
(mdbioproducts DJ8), FITC anti-mouse Ter119 (BioLegend Ter119), PE-anti-mouse 
CD71 (BioLegend L5), APC anti-mouse DYKDDDDK (BioLegend RI7217), Brilliant 
Violet 570 anti-mouse CD45.1 (BioLegend A20) and Brilliant Violet 785™ anti-mouse 
CD45.2 (BioLegend 104), APC anti-mouse CD45 (BioLegend 30-F11). Cell analysis 
was done using BD FACSDiva v8.01 Software and figure displayed dot plots and 
histograms were obtained using FlowJo v10.5 software (FlowJo, LLC).  
Cytokine quantification. We used MesoScale Discovery IL-33 V-Plex assay kit 
(product code K152XBD-1) and human IL-33 Duoset ELISA  kit (DY3625, R&D 
systems) according to manufacturer's instructions. Measurements were performed 
blindly by the Core Biochemical Assay lab at Addenbrookes Hospital, the University 
of Cambridge, Cambridge, UK. 
Quantitative RT-PCR. For gene expression analysis, RNA from sorted RPM, Pre-
RPM and Monocytes were isolated using an RNAeasy mini kit (Qiagen). RT-PCR 
was performed using a QuantiTect Reverse Transcription kit (Qiagen). Real-time 
PCR was performed on 5 µl cDNA product (diluted 10 to 20 times) using SYBR 
Green qPCR mix (Eurogentec) on a Roche Lightcycler. Primer sequences are: 
human SPIC forward 5’-ACGGTAATTAACAGTGCTGCG-3’ and reverse 5’-
GCTGGAGAAGAGTGGGTTGT-3’, human HMOX1 forward 5’-
TAGAAGAGGCCAAGACTGCG-3’ and reverse 5’- 
GGGCAGAATCTTGCACTTTGTT-3’, human TREML4 forward 5’- 
AGACCAGGAAATCAAGAGCCC-3’ and reverse 5’-AAACCTCGTCACTGCTGTCC-
3’, human VCAM1 forward 5’-GTTTGCAGCTTCTCAAGCTTTT-3’ and reverse 5’-
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AGATGTGGTCCCCTCATTCG -3’, human LCN2 forward 5’-
GCCCTGAAATCATGCCCCTA-3’ and reverse 5’-TCCCCTGGAATTGGTTGTCC-3’, 
human BACH1 forward 5’-TCGCGTAAGAAAAGCCGAG-3’ and reverse 5’-
CATCAACCATATTGTGCGAGGC-3’, human IL1RL1 forward 5’- 
CCCTCTGTCTTTCAGTTTGGTTGA-3’ and reverse 5’- 
ACGACAGTGAAGGTCACCAC-3’. Mouse Spic forward 5'-
ACTGGAGAGGTGTAACAAATGGT-3' and reverse 5'-
CAAACAGCCGAAGCTTTCTCC-3', mouse Treml4 forward 5'-
AAGCACAGCCACCATCTTTATG-3' and reverse 5'-
GCACACAGAAAACTGACAGCA-3', mouse Bach1 forward 5'-
CTCTGAGACGGACACGGAAG-3' and reverse 5'-CCTTCTGCGGATGTCATGGA-3', 
mouse Itgam (Cd11b) forward 5'-GTGAGGTCTAAGACAGAGACCAA-3' and reverse 
5'-TGCCGCTTGAAAAAGCCAAG-3', mouse Hmox1 forward, 5'-
GCTAGCCTGGTGCAAGATACT-3' and reverse 5'-TGGGGGCCAGTATTGCATTT-3', 
mouse Il1rl1 forward 5'-CCAGCCCTTCATCTGGGTATC-3' and reverse 5'-
TGGCAATGGCACAGGATAGT-3', mouse Lcn2 forward 5'-
CTGTCCCAATCGACCAGTGT-3' and reverse 5'-CCAGCTCCCTCAATGGTGTT-3', 
mouse Adgre1 (F4/80) forward 5'-AATCGCTGCTGGTTGAATACAG-3' and reverse 
5'-CCAGGCAAGGAGGACAGAGTT-3', mouse Vcam1 forward 5'-
CCGGCATATACGAGTGTGAA-3' and reverse 5'-GATGCGCAGTAGAGTGCAAG-3'. 
These experiments were independently repeated three times and each treatment 
consisted of triplicate samples. 
PKH26-staining of Mouse RBCs and analysis of PKH26-stained cells. Anti-
mouse CD47 Fab antibody treated RBCs were stained with PKH26 (Sigma) 
according to the manufacturer’s protocol.  Briefly, 250 µL of RBCs were mixed with 
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2.25 mL diluent C from the PKH26 cell linker kit and incubated with 2 µM PKH26 dye 
for 5 min at room temperature. The staining reaction was stopped by the addition of 
2.5 mL FBS for 1 min, followed by further dilution with 5 mL PBS. Cells were then 
washed three times with PBS and resuspended at 1x1010/200 µL for intravenous 
injection. 24 hours after i.v. injection, spleens were collected and single-cell 
suspensions were prepared by mechanical disruption. Following incubation in Fc 
block, splenocytes were labelled with antibodies against Ly6G, CD11b and F4/80 
and analysed by flow cytometry (Fortessa) for PKH26+ cells in splenic monocytes 
(CD11bhi F4/80-) or pre-RPM (CD11bhi F4/80lo) or RPM (CD11blo/- F4/80hi) or 
neutrophil (Ly6GhiCD11b+) population. 
Crude RBC lysates preparation. Human or mouse whole blood was collected in 
EDTA-treated blood collection tubes, followed by centrifugation at 400g for 10 min. 
The RBC were transferred to new tubes and washed twice in PBS. The samples 
were incubated with RBC lysis buffer at room temperature for 10 minutes. After 
centrifugation at 13,000 g for 15 min at 4oC, the supernatants were passed through 
Amicon ultra (50 kDa) cutoff filter to remove haemoglobin (64 kDa), followed by a 
centrifugation at 7,000 g for 20 min at 4oC.  
Enriched human RBC lysates preparation. The positive selection of human 
erythrocytes from fresh human whole blood was performed using anti-CD235a 
(Glycophorin A)-conjugated microbeads and MACS LS columns (Miltenyi Biotec) 
according to manufacturer’s instructions. Enriched erythrocyte preparations (2e8 
cells/ml) were lysed in PBS/0.1% Triton X100 at 4oC and lysates snap frozen on dry 
ice.  
SDS-PAGE and western blot analysis. Samples were analysed by SDS-PAGE on 
NuPAGE Novex 4-12% or 12% Bis-Tris mini gels (Invitrogen) with MOPS running 
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buffer (Invitrogen) according to manufacturer’s instructions under reducing conditions. 
All samples were reduced by heating to 95oC for 3 min in SDS-PAGE buffer 
containing 2% beta-mercaptoethanol. Proteins were transferred to nitrocellulose 
membranes (Invitrogen) and detected by Western blotting. IL-33 was detected with 
an anti-mouse IL-33 antibody (R&D systems AF3626) and anti-human IL-33 
antibodies (R&D systems AF3626 and BioRad AHP1482, AHP1626). 
Immunoreactive proteins were identified with HRP-conjugated secondary antibodies 
(R&D systems HAF008, 005 and 109) and Supersignal West Femto substrate 
(Pierce 34095) and visualized on LI-COR cDigit. 
RNA-sequencing analysis in splenocytes. RNA was extracted from freshly 
sorted splenic monocytes, pre-RPM and RPM, using the RNEasy plus micro kit 
(Qiagen). RNA libraries were prepared using the SMARTer stranded total RNA-
Seq v2 kit (Takara) and sequenced using Illumina NovaSeq (2x50bp), obtaining 
approximately 20 million reads per sample.  
ATAC-sequencing analysis in splenocytes. ATAC-seq was performed according 
to the published Omni-ATAC protocol (Corces et al., 2017). Briefly, nuclei were 
purified from 5x104 freshly sorted splenic monocytes, pre-RPM and RPM. 
Transposition reactions were performed in 50ml using Tn5 transposase (Illumina) 
for 30 min at 37oC. Libraries were prepared using the recommended Nextera 
barcodes (Corces et al., 2017) and the number of PCR amplification cycles was 
determined empirically as the number of cycles required to generate 25% of the 
maximum of a 5µl aliquot, as recommended (Corces et al., 2017). Libraries were 
cleaned up using the Minelute PCR purification cleanup kit (Qiagen) followed by 
AMPure XP beads (Beckman Coulter) and quantified using quantitative PCR (Kapa 
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Biosystems). 5nM libraries were multiplexed and sequenced using Illumina 
NovaSeq (2x50bp), obtaining approximately 80 million reads per barcoded sample. 
Differential gene expression (DGE) analysis. Reads were mapped to 
Ensembl/GRCm38.95 using STAR (v2.5.1) 
(https://github.com/alexdobin/STAR/releases/tag/2.5.1b) with default parameters, 
trimmed with cutadapt 2.5 (https://pypi.org/project/cutadapt/2.5/) under Python 
3.6.2 (parameters: --nextseq-trim=20 -m 15 for the R1 reads and --nextseq-trim=20 
-m 15 -u 3 for the R2 reads) and counted using Subread-Feature Counts (v1.6.2) 
(https://sourceforge.net/projects/subread/files/subread-1.6.2/). DGE analysis was 
performed using DESeq2 (v1.25.9) 
(http://bioconductor.org/packages/release/bioc/html/DESeq2.html). Heatmaps were 
generated using the heatmap.2 function from the R Package gplots version 
3.0.1.1 (https://cran.r-project.org/src/contrib/Archive/gplots/). Lists of differentially 
expressed genes were submitted to Pathway analysis using Ingenuity Systems 
Pathway analysis software (Qiagen).  
ATAC peak calling & Meme. Reads were quality trimmed using TrimGalore 
(https://github.com/FelixKrueger/TrimGalore/releases/tag/0.6.4) with a quality 
Phred score cutoff of 20 and a minimum required sequence length for both reads 
before a sequence pair gets removed set to 20 bp. Trimmed reads were mapped to 
Ensembl/GRCm38.95 using Bowtie2 (https://sourceforge.net/projects/bowtie-
bio/files/bowtie2/2.3.5.1/) with standard parameters. Peaks were called using 
Genrich (https://github.com/jsh58/Genrich#quick) and excluding mitochondrial 
reads. Differential peak analysis was performed using BEDtools 2.29.0 
(https://github.com/arq5x/bedtools2/releases/tag/v2.29.0). Motif enrichment was 
performed using Meme-Chip (Ma et al., 2014) with default parameters. 
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Statistical analysis. Data are represented as mean ± SEM. Differences between 
values were examined using the parametric two-tailed unpaired Student's t-test or 
two-way ANOVA. 
Data and code availability. All sequencing data have been deposited in the 
National Centre for Biotechnology Information Gene Expression Omnibus (GEO) and 
are accessible with series accession number (GSE146782). All other relevant data 





Supplemental Information includes seven figures and four tables can be found with 
this article online at XXX. 
Table S1 related to Figures 6 and 7. Differentially expressed genes in wild-type (wt) 
and Il1rl1-/- (ko) monocytes, adjusted p-value<0.05. 
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Rank	 Gene	Symbol	 log2	FC		 p	
1	 Gm25939	 -2.7	 3.6E-18	
2	 Golph3l	 -2.6	 4.1E-11	
3	 Gata2	 -2.2	 2.1E-06	
4	 Il18r1	 -2.2	 2.0E-08	
5	 Ncr1	 -2.1	 3.4E-06	
6	 Prf1	 -2.1	 3.6E-05	
7	 Gzma	 -2.0	 4.9E-02	
8	 Hdc	 -1.9	 3.2E-02	
9	 Gimap4	 -1.8	 4.9E-04	
10	 Hjurp	 -1.8	 2.7E-33	
33	 Ets1	 -0.9	 8.8E-03	
Genes	up-regulated	in	Il1rl1-/-	Pre-RPM	
Rank	 Gene	Symbol	 log2	FC		 p	
1	 Gm25813	 2.9	 1.8E-16	
2	 Cux2	 2.8	 5.1E-13	
3	 Gm25360	 2.6	 9.0E-19	
4	 Adam23	 2.0	 1.6E-07	
5	 Mfap1a	 1.9	 7.3E-05	
6	 Pou6f1	 1.7	 1.9E-03	
7	 Adgrl3	 1.6	 4.4E-02	
8	 Il1rl1	 1.5	 3.6E-05	
9	 Dst	 1.1	 2.6E-03	

































































































































































































































































































































































Figure S1 related to Figure 1. IL-33 up-regulates hemin-induced Spic expression and promotes the development 
of a red pulp macrophage (RPM) phenotype in vitro and in vivo. A, Spic mRNA expression in mouse bone marrow-
derived (BMDM) macrophages stimulated in vitro for 4 days with individual cytokines (10ng/mL), hemin (40µM), or a 
combination of hemin and individual cytokines, compared to no treatment (NT). Data are representative of 3 independent 
experiments. B, Human macrophages were developed in culture from isolated blood CD14+ monocytes (HuCD14+) and 
were treated in vitro for 4 days with hemin, IL-33, or a combination of hemin + IL-33, and were assessed for mRNA 
expression of Spic and other typical red pulp macrophage-associated genes, including Treml4, Lcn2, Hmox1, Il1rl1 and 
Vcam1. Data are representative of 3 independent experiments. C, Representative examples of flow cytometry staining 
for Spic-EGFP, CD11b and F4/80 in splenocytes of C57/Bl6 Spicigfp/igfp reporter mice. Splenic RPM are CD11blo/– F4/80hi
Spic-EGFPhi, whereas most Spic-EGFPint cells are CD11bhi F4/80lo/– pre-RPM and monocytes. Data are representative 
of more than 3 independent experiments. D, Splenic monocytes (CD11bhi F4/80–), pre-RPM (CD11bhi F4/80lo) and RPM 
(CD11blo/– F4/80hi) were cell-sorted by flow cytometry and were assessed for mRNA expression of Spic and other typical 
RPM-associated genes. Data are representative of 3 pooled mice per group. E, Cell-sorted (flow cytometry) splenic 
monocytes (CD11bhi F4/80–) and pre-RPM (CD11bhi F4/80lo) were treated in vitro for 4 days with hemin (40 µM), IL-33 
(10 ng/mL), or a combination of hemin + IL-33, and compared to untreated cells for the expression of Spic and Hmox1. 
Data are representative of 3 pooled mice per group. F, C57/Bl6 Spicigfp/igfp reporter mice were injected intraperitoneally 
once a day for 4 days with either phosphate buffered saline (PBS), IL-33 (1µg), hemin (500µg), or IL-33 + hemin, and 
spleens were assayed by flow cytometry for splenic RPM (CD11blo/- Spic-EGFPhi) and pre-RPM (CD11bhi Spic-
EGFPlo/int). Quantification of (G) pre-RPM and (H) RPM (percentages among CD11clow Ly6Glow NK1.1low SSC-Alow cells). 
Each dot in G and H represents a separate mouse. ****P<0.0001; ***P<0.001.
WT Il1rl1-/- Il33-/-
Figure S2



















































































































































































































































Figure S2 related to Figure 2. IL1RL1 (ST2) signalling controls the development of splenic red pulp 
macrophages (RPM). A, Spic, Hmox1 and Lcn2 mRNA expression in wild type (WT) and Il1rl1–/– mouse 
bone marrow-derived macrophages stimulated in vitro for 4 days with IL-33 (10 ng/mL), hemin (40 µM), or a 
combination of hemin and IL-33, compared to untreated cells (NT). Data are representative of 5 independent 
experiments per group. B, Representative examples of IL1RL1 (ST2) expression in splenic RPM (CD11blo/¾
F4/80hi) of wild-type (WT), Il1rl1–/– (negative control), and Il33–/– mice. C, Representative examples of Spic-
EGFP and F4/80 expression by flow cytometry in spleens of neonates (Day 1 and Day 2) and young (4 
weeks old) mice. D, Quantification of F4/80hi Spic-EGFPhi, F4/80int Spic-EGFPint and F4/80lo Spic-EGFPlo
cells (percentages among CD11clow Ly6Glow NK1.1low SSC-Alow cells). E, Quantification of RPM and pre-
RPM (absolute numbers) in spleens of 6 weeks and 42 weeks old wild type (WT), Il33–/–, and Il1rl1–/– mice. 
F, Quantification of other immune cell types in spleens of 6 weeks old wild type (WT) and Il1rl1–/– mice. 
FOB= Follicular B cells; MZB= marginal zone B cells; MM= Metallophilic macrophages; MZM= Marginal 
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Figure S3 related to Figure 2. Cell-autonomous requirement of IL1RL1 expression in bone marrow-derived 
monocytes during the development of splenic red pulp macrophages (RPM). A, Representative scheme of 
lethal irradiation and reconstitution of CD45.2 WT mice with either 50% CD45.1 + 50% CD45.2 WT or 50% CD45.1 + 
50% CD45.2 Il1rl1–/– bone marrow. 10 weeks later, mice were injected intraperitoneally once a day for 3 days with 
either phosphate buffered saline (PBS), or IL-33+hemin (see Methods), before they were assayed for CD45.1 and 
CD45.2 positive cells by flow cytometry. B, C, Quantification of CD45.1 positive cells among splenic monocytes 
(CD11bhi F4/80–), pre-RPM (CD11bhi F4/80lo) and RPM (CD11blo/– F4/80hi) by flow cytometry. Each dot represents a 
separate mouse. **P<0.01, ****P<0.001. D-F, CD45.1 wild-type (WT) mice were lethally irradiated and reconstituted 
with either 100% CD45.2 WT or 100% CD45.2 Il1rl1–/– (D) bone marrow. 8 weeks after bone marrow reconstitution, 
spleens were assayed for CD45.1 and CD45.2 positive RPM (CD11blo/– F4/80hi) and pre-RPM (CD11bhi F4/80lo) by 
flow cytometry. Quantifications (percentages and absolute numbers) are shown in (E) for RPM, and in (F) for pre-
RPM. Each dot in E and F represents a separate mouse. **P<0.001. ****P<0.0001.
WT
Il1rl1-/-
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Figure S4 related to Figure 3. Impact of IL1RL1 (ST2) signalling on the function of splenic red pulp 
macrophages (RPM) . Representative examples (6 mice per group) of flow cytometry staining (A) and 
quantification (B) of uptake of PKH26-labelled red blood cells by splenic RPM, pre-RPM, monocytes and 
neutrophils after injection into WT and Il1rl1–/– mice. C, Quantification of hematocrit (HCT), red blood cell 
(RBC) counts, serum (TIBC), hemoglobin (HGB), transferrin and ferritin in young (6 weeks) and old (42 
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Figure S5 related to Figure 5. IL-33 signaling controls the development of red pulp macrophages 
(RPM). A, Representative examples of flow cytometry staining and quantification of RPM and pre-RPM 
(% among  CD11clow Ly6Glow NK1.1low SSC-Alow cells) in spleens of wild type (WT) and Il33–/– mice, 9 
mice per group. Data are representative of at least 5 independent experiments. B, Representative 
examples and quantification (among CD11clow Ly6Glow NK1.1low SSC-Alow cells) of flow cytometry 
staining for splenic pre-RPM (CD11b+ F4/80lo) and RPM (CD11blo/– F4/80hi) in mice injected 
intraperitoneally once a day for 3 days with either phosphate buffered saline (PBS), IL-33 (1 µg), hemin 
(500 µg), or IL-33 + hemin, 5 mice per group. Data are representative of at least 4 independent 
experiments. C, Representative examples and quantification of splenic RPM (CD11blo/– EMR1hi) in wild-
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Figure S6 related to Figure 5. IL-33 in red blood cell (RBC) progenitors and mature RBCs. A, Detection of IL-33 in 
human red blood cell (RBC) lysates using western blotting and 2 different anti-IL-33 antibodies. Recombinant full-length 
human IL-33 is included as a positive control. B, Quantification of IL-33 protein in RBC lysates. Normal human bronchial 
epithelial cells (NHBE) are used as positive controls. C, Representative examples of flow cytometry showing Il33-Citrine+
RBC progenitors (Ter119+/CD71+ or CD71–) in RBC-depleted bone marrow of wild type (WT) and Il33Citrine/Citrine reporter mice. 
D, Representative examples of flow cytometry staining for pro-erythroid cells (ProE, Ter119int/CD71hi), and erythroblast 
subsets A (less mature, Ter119hi CD71hi FSC hi), B (intermediate maturation, Ter119hi CD71hi FSClo) and C (most mature, 
Ter119hi CD71lo/– FSClo) in the bone marrow of wild type mice. IL1RL1 (ST2)+ cells are enriched in pro-erythroid cells and 
erythroblast B subset. E, recombinant murine IL-33-Flag was incubated with whole bone marrow cells of WT and Il1rl1–/– mice 
for 60 min, which was followed by extracellular and intracellular staining for Flag. Results are gated on Ter119hi cells 
(erythroblasts) and mean fluorescence intensity (MFI) is shown. Data are representative of 3 independent experiments. F, 
Quantification (% among CD11clow Ly6Glow NK1.1low SSC-Alow cells) of splenic RPM (CD11blo/– F4/80hi) by flow cytometry in 
WT and Il33–/– mice. Some Il33–/– mice were reconstituted with either WT, Il33–/–, or Il1rl1–/– RBCs (see Methods) prior to 
assessment of splenic RPM. **P<0.05, ***P<0.01, ****P<0.001.






































Figure S7 related to Figures 6 and 7. ATAC-sequencing and RNA-sequencing of splenic monocytes, pre-RPM and 
RPM. A, Examples of peak calling of accessible chromatin by ATAC-seq from splenic monocytes (CD11bhi F4/80–), pre-RPM 
(CD11bhi F4/80lo ) and RPM (CD11blo/– F4/80hi) from WT and Il1rl1–/– mice, n=4 per group. B, Top upstream transcriptional 
regulators for differentially expressed genes (DGE) in WT and Il1rl1–/– pre-RPM (adjusted p-value <0.05), identified by 
Ingenuity pathway analysis.
